Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing Remitting Multiple Sclerosis RRMS”

Showing 20 of 0 results

Not applicableStudy completedNCT01804647
What this trial is testing

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease

Who this might be right for
Multiple Sclerosis (MS)Relapsing-Remitting MSPrimary Progressive MS+2 more
GeNeuro Innovation SAS 58
Post-approval studies (Phase 4)Ended earlyNCT00202995
What this trial is testing

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 91
Post-approval studies (Phase 4)Study completedNCT01578330
What this trial is testing

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Who this might be right for
Multiple SclerosisRelapsing-Remitting
Novartis Pharmaceuticals 42
Not applicableStudy completedNCT00818038
What this trial is testing

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 30
Large-scale testing (Phase 3)Ended earlyNCT03283397
What this trial is testing

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bosnalijek D.D 301
Post-approval studies (Phase 4)Study completedNCT02373098
What this trial is testing

Fingolimod Effect on Cytokine and Chemokine Levels

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 126
Post-approval studies (Phase 4)Study completedNCT02205489
What this trial is testing

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Genzyme, a Sanofi Company 58
Not applicableStudy completedNCT02776072
What this trial is testing

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Biogen 2,978
Post-approval studies (Phase 4)Study completedNCT02587065
What this trial is testing

Plegridy Satisfaction Study in Participants

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen 193
Not applicableUnknownNCT05245344
What this trial is testing

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Neuromyelitis OpticaHealthy
Neuromed IRCCS 154
Testing effectiveness (Phase 2)Study completedNCT02493049
What this trial is testing

Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of Calgary 17
Not applicableStudy completedNCT05604092
What this trial is testing

Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Assiut University 63
Testing effectiveness (Phase 2)Study completedNCT01742052
What this trial is testing

Dose-finding Study of MT-1303

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Tanabe Pharma Corporation 415
Not applicableStudy completedNCT05304520
What this trial is testing

Tysabri Participant Preference

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen 318
Not applicableStudy completedNCT03134573
What this trial is testing

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Who this might be right for
Multiple Sclerosis
Bayer 96
Large-scale testing (Phase 3)WithdrawnNCT01975298
What this trial is testing

Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.
Testing effectiveness (Phase 2)Study completedNCT01185821
What this trial is testing

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 185
Testing effectiveness (Phase 2)Ended earlyNCT02222948
What this trial is testing

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Genzyme, a Sanofi Company 112
Early research (Phase 1)Study completedNCT01738347
What this trial is testing

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Who this might be right for
Relapsing-remitting Multiple Sclerosis (rrMS)
GE Healthcare 30
Large-scale testing (Phase 3)Study completedNCT00605215
What this trial is testing

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 1,331
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation